• ATS 2023 |

    Model-Based Dose Selection for Phase 3 Trials of the Selective P2X3 Antagonist Camlipixant in Refractory Chronic Cough.

    Read More

  • ATS 2023 |

    Response In Patient-Reported Cough Severity in SOOTHE, A Phase 2b Trial of Camlipixant in Refractory Chronic Cough (Slides).

    Read More

  • ATS 2023 |

    Response In Patient-Reported Cough Severity in SOOTHE, A Phase 2b Trial of Camlipixant in Refractory Chronic Cough (Poster).

    Read More

  • ASCPT 2023 |

    In Vitro, In Silico, and Clinical Investigations of BLU-5937 as Perpetrator of Drug-Drug Interactions.

    Read More

  • AAAAI 2023 |

    Burden of Cough in Refractory Chronic Cough Population Enrolled in a Phase 2b Study of the P2X3 Antagonist BLU-5937.

    Read More

  • AAAAI 2023 |

    Cough Associated Diagnostic Journey of Participants in a Phase 2b Study in Refractory Chronic Cough.

    Read More

  • CHEST 2022 |

    Prior Specialist Consultations and Treatments in a Refractory Chronic Cough Population Enrolled In a Phase 2b Study of the P2X3 Antagonist BLU 5937.

    Read More

  • ERS 2022 |

    Efficacy in SOOTHE, A Phase 2b Trial of BLU-5937 In Refractory Chronic Cough, Was Not Dependent of Taste Disturbance Adverse Events.

    Read More

  • ERS 2022 |

    Characteristics of Participants with Refractory Chronic Cough Enrolled in A Phase 2b Trial of BLU-5937.

    Read More

  • ERS 2022 |

    Improvements In Awake Cough Frequency In Participants Treated With BLU-5937 In A Phase 2b Trial of BLU-5937 in Refractory Chronic Cough.

    Read More

  • ICS 2022 |

    Development of BLU-5937 for the Treatment of Refractory Chronic Cough.

    Read More

  • ATS 2022 |

    Safety And Efficacy of BLU-5937 In the Treatment of Refractory Chronic Cough from the Phase 2b SOOTHE Trial.

    Read More

  • ATS 2022 |

    Safety And Efficacy of BLU-5937 In the Treatment of Refractory Chronic Cough from the Phase 2b SOOTHE Trial.

    Read More

  • ATS 2022 |

    Responders Analyses in Objective 24H Cough Frequency in SOOTHE, A Phase 2b Trial of a Selective P2x3 Antagonist in Refractory Chronic Cough.

    Read More

  • ATS 2022 |

    Improvements in Cough Severity and Quality of Life in SOOTHE, A Phase 2b, Dose Finding Trial of BLU-5937 in Refractory Chronic Cough.

    Read More

  • ERS 2021 |

    Improvements in cough severity and cough related quality of life in a phase 2 trial with BLU 5937 in refractory chronic cough.

    Read More

  • ACC 2021 |

    Update on the Development of BLU 5937 for the Treatment of Refractory Chronic Cough.

    Read More

  • ATS 2021 |

    Design of SOOTHE, a Phase 2b Dose Finding Study with BLU 5937, a Selective P2X3 Antagonist, in Refractory Chronic Cough.

    Read More

  • ATS 2021 |

    Improvements in Cough Frequency over 24 Hours with BLU 5937, a Selective P2X3 Antagonist, in Patient Subgroups Defined by Baseline Awake Cough Frequencies.

    Read More

  • ATS 2021 |

    Baseline Characteristics and Burden of Disease in Populations Defined by Cough Frequency Tiers in RELIEF, a Phase 2 Study on the Efficacy and Safety of BLU 5937 in Refractory Chronic Cough.

    Read More

  • ICS 2021 |

    Results of RELIEF, a Phase 2a Study with BLU-5937 in Refractory Chronic Cough.

    Read More

  • ICS 2021 |

    BLU-5937, A Potent and Selective P2X3 Receptor Antagonist, Presents a Promising New Approach for the Treatment of Chronic Pruritus in Atopic Dermatitis Patients.

    Read More

  • ESDR 2019 |

    BLU-5937; A Potent and Selective P2X3 Antogonist, for the Treatment of Chronic Itch: Evidence from Preclinical Studies.

    Read More

  • ACC 2019 |

    BLU-5937: A Highly Selective P2X3 Homotrimeric Receptor Antagonist, Exhibits Excellent Pharmacokinetic and Safety Profile Including Improved Taste Safety Profile in Healthy Subjects.

    Read More

  • ATS 2019 |

    BLU-5937 a Highly Selective P2X3 Homotrimeric Receptor Antagonist with Improved Taste Safety Profile in Healthy Subjects.

    Read More

  • ELSEVIER |

    BLU-5937: A selective P2X3 antagonist with potent anti-tussive effect and no taste alteration.

    Read More

  • ICS 2018 |

    BLU-5937: A Selective P2X3 Antagonist With Potent Anti-Tussive Effect and No Taste Alteration.

    Read More